Form 4: NAMS CSO Sells Over $1.6M in Company Shares

NewAmsterdam Pharma's Chief Scientific Officer and Director, Johannes Jacob Pieter Kastelein, reported selling over $1.6 million in company ordinary shares.

Summary

• Johannes Jacob Pieter Kastelein, Chief Scientific Officer and Director of NewAmsterdam Pharma Co N.V. (NAMS), sold a total of 45,481 ordinary shares.
• The transactions occurred on February 20, 2026.
• The first sale involved 14,692 shares at a weighted average price of $35.00 per share, with prices ranging from $34.24 to $35.23.
• The second sale involved 30,789 shares at a weighted average price of $35.46 per share, with prices ranging from $35.24 to $35.86.
• Following these sales, Kastelein beneficially owns a total of 137,789 ordinary shares (84,289 from the first transaction and 53,500 from the second transaction).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative signal, as significant insider selling by a key executive and director can erode investor confidence, even if driven by personal financial planning.

Negatives

• A key executive and director, the Chief Scientific Officer, sold a significant number of company shares.
• The sale of 45,481 shares represents a notable reduction in the insider's direct holdings.
• Insider selling can be interpreted by the market as a lack of confidence in the company's near-term prospects or a belief that the stock is fully valued.

Risks

• Potential negative market perception due to insider selling, which could lead to downward pressure on the stock price.
• Reduced alignment of interests between management and shareholders if significant insider holdings are divested.

Future Outlook

Not applicable, as this filing is an insider transaction report and does not typically contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider selling, particularly by a Chief Scientific Officer and Director, can sometimes signal a lack of confidence in the company's near-term prospects or a belief that the stock is fully valued. While individual financial planning needs can drive such sales, the market often scrutinizes these transactions for underlying signals about future performance.

Stakeholder Impact

• Shareholders may interpret the insider sale as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Recommendation

While insider selling is generally a negative signal, the context of the sale (e.g., a pre-arranged 10b5-1 plan, personal liquidity needs) is not fully disclosed in this filing alone. A 'hold' recommendation allows for further analysis of the company's fundamentals and broader market conditions before making a definitive 'sell' decision, as the sale itself doesn't necessarily indicate a fundamental deterioration. However, investors should monitor future insider activity and company news closely for additional insights.

Keywords

NewAmsterdam Pharma, NAMS, Form 4, insider trading, stock sale, Johannes Jacob Pieter Kastelein, Chief Scientific Officer, Director, equity transaction